Monograph Details
|
|
Endocrine System
> Diabetes
|
|
GLUCAGON |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antihypoglycemic. |
| Generic Name |
|
Glucagon (recombinant) 1mg/mL; pwd for IM, IV, or SC inj after reconstitution. |
| Indications |
|
Acute hypoglycemia. |
| Adults and Children |
|
<20kg: 0.5mg or 20–30micrograms/kg. ≥20kg: 1mg. If patient does not respond in 15 minutes, may give 1–2 more doses. |
| Contraindications |
|
Pheochromocytoma. |
| Precautions |
|
If ineffective, IV dextrose must be given. When patient responds, supplemental carbohydrate should be given (esp. children). Type 1 diabetics may be less responsive. History of insulinoma or pheochromocytoma. Insufficient glycogen stores (e.g., starvation, adrenal insufficiency, chronic hypoglycemia). Monitor serum potassium. Pregnancy (Cat.B). Nursing mothers. |
| Adverse Reactions |
|
GI upset, hypersensitivity reactions (urticaria, respiratory distress, hypotension). |
| How Supplied |
|
Emergency kit (1mg)—1 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
